Member Info for OAPK20

Justin Podcast - Dest PUMPED

Typical :-)

Results end of August ?

Other opportunity had to take. Small profit here. Can always come back if it drops to 0.25 or holds current

Bailed. good luck.

Was 22/2/23 and an increase in holdings. Despite the selling and drop in share price there has not been anymore TR1's issued.

Cizzle need to provide and update about the collaboration with FairJourneyBiologics and the development and supply of the Proprietary key monoclonal antibodies and the other detector proteins required for the ELISA.

They need to show that their test works and can be commercialised via US and China partnerships.

Takes time but the longer it goes ......

Thanks Rose.

Been adding when I can. Excited about the deal.

If he moves things forward and increases shareholder value then yes.

Returning Chairman Sir Nigel Rudd said: "My confidence in Destiny can be traced back 20 years to my first investment in the business. It is with great pleasure that I can return to the Company at such an exciting time, as we move towards the commercialisation of our products. Our recent market research is indicating that there is a blockbuster, $2bn plus opportunity with the XF-73 programme in the US alone. And our NTCD-M3 programme is Phase 3 ready, with the clinical development and regulatory investment required, coming from our partner Sebela."

Dilution ?

Trading opportunity Pumpers starting. 35p placing shares to be flipped. Buy n hold now or trade the pump?

“Pumps” it up nicely

Results of surface sampling programme at Argo Project, USA, confirm and define surface gold mineralisation of over 10 g/t

Lexington Gold (AIM: LEX), the gold exploration and development company with projects in North and South Carolina, USA, is pleased to announce assay results received in respect of the completed surface exploration and trenching sampling programme at its Argo Project (the "Argo Project" or "Argo").

Release 21/7/23 - MURF/Conduit merger NASDAQ listing

Form 425 - Prospectuses and communications, business combinations

On July 21, 2023, the Company made available an investor presentation in connection with the proposed Business Combination. A copy of the investor presentation is furnished as Exhibit 99.1 to this 8-K.

Reading makes you wonder whether CIZ will hold their PUT option shares given the potential implied pro-forma enterprise value of $716.55MM and pro-forma equity value of $752.48MM.

“Dr Lewis-Hall and Dr Tapolczay were part of the team that founded Springworks Therapeutics NASDAQ listed oncology company which licensed molecules from Pfizer which raised approx $186.3MM on listing and with a current MCAP of $1.65BN (July 2023)”

“Conduits model is based on (and we believe further evolves) the Springworks model. We believe that Conduit is more capital efficient as our molecules have already undergone phase 1 testing and Conduit is disease agnostic. Conduit intends to licence its compounds following phase 2 data and as a result we believe that Conduit has the potential to provide SIGNIFICANT returns to investors”

Put option - Cizzle for a total consideration of approximately GBP3.25 million - $10 per share.

What value if they hold on to Conduit shares until Phase 2 data for AZD1656?

Come on CIZ give us an update

Overall world revenue for Cancer biologics market, 2023 to 2033 in terms of value the market will surpass US$ 115.9 billion in 2023, our work calculates. We predict strong revenue growth through to 2033.

Looking forward to this update when it lands.

Proposed US pricing for Tutivia(TM)

Medicare proposed gapfill median rate of $2,650 per test.

This proposed rate is currently open for public comment before it is finalised later this year. Following finalisation, the price in the CLFS is valid for a period of three years from 1 January 2024, after which it is subject to further review.

Eli Lilly don’t they do Tampons ?

Or is he just being nice about the interim CEO ?

Late reporting should be banned

It’s down over 40% from recent highs

Key word “producing”